Astellas Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment

  If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations in the European Union (EU)

- A decision on the EU marketing authorisation is expected by June 2024-

https://www.biospace.com/article/releases/astellas-receives-positive-chmp-opinion-for-xtandi-in-additional-recurrent-early-prostate-cancer-treatment-setting/